Leerink Partnrs Has Negative Outlook of TNDM FY2028 Earnings

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) – Investment analysts at Leerink Partnrs decreased their FY2028 EPS estimates for Tandem Diabetes Care in a research note issued to investors on Monday, November 25th. Leerink Partnrs analyst M. Kratky now forecasts that the medical device company will earn $0.00 per share for the year, down from their prior estimate of $0.01. The consensus estimate for Tandem Diabetes Care’s current full-year earnings is ($1.73) per share.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.08. The company had revenue of $243.97 million during the quarter, compared to analysts’ expectations of $224.14 million. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The business’s quarterly revenue was up 31.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.38) earnings per share.

TNDM has been the topic of a number of other research reports. Barclays lifted their price target on shares of Tandem Diabetes Care from $58.00 to $60.00 and gave the company an “overweight” rating in a research report on Friday, November 8th. Royal Bank of Canada started coverage on shares of Tandem Diabetes Care in a research report on Wednesday, October 2nd. They set an “outperform” rating and a $65.00 target price for the company. Canaccord Genuity Group lowered their price target on Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Piper Sandler reissued an “overweight” rating and set a $55.00 price objective (up previously from $50.00) on shares of Tandem Diabetes Care in a research report on Friday, August 2nd. Finally, Robert W. Baird lowered their target price on Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating on the stock in a report on Thursday, November 7th. Five analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $54.25.

Tandem Diabetes Care Stock Up 3.9 %

TNDM opened at $31.22 on Tuesday. The firm has a market cap of $2.05 billion, a P/E ratio of -15.56 and a beta of 1.36. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. The business has a 50 day moving average price of $35.65 and a 200 day moving average price of $41.04. Tandem Diabetes Care has a twelve month low of $18.45 and a twelve month high of $53.69.

Institutional Trading of Tandem Diabetes Care

Institutional investors have recently bought and sold shares of the stock. Sei Investments Co. lifted its holdings in shares of Tandem Diabetes Care by 125.8% during the first quarter. Sei Investments Co. now owns 17,349 shares of the medical device company’s stock valued at $614,000 after acquiring an additional 9,666 shares during the period. Vanguard Group Inc. boosted its position in Tandem Diabetes Care by 0.4% in the first quarter. Vanguard Group Inc. now owns 7,052,570 shares of the medical device company’s stock valued at $249,732,000 after buying an additional 30,664 shares in the last quarter. BOKF NA grew its stake in Tandem Diabetes Care by 28.9% during the first quarter. BOKF NA now owns 23,817 shares of the medical device company’s stock worth $806,000 after buying an additional 5,345 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Tandem Diabetes Care by 5.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 38,732 shares of the medical device company’s stock worth $1,372,000 after buying an additional 1,985 shares in the last quarter. Finally, Silvercrest Asset Management Group LLC raised its stake in shares of Tandem Diabetes Care by 4.3% in the first quarter. Silvercrest Asset Management Group LLC now owns 266,158 shares of the medical device company’s stock valued at $9,425,000 after acquiring an additional 10,907 shares during the last quarter.

Insider Activity

In other news, Director Kim D. Blickenstaff sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $30.00, for a total value of $300,000.00. Following the sale, the director now directly owns 195,190 shares in the company, valued at approximately $5,855,700. This represents a 4.87 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 2.20% of the company’s stock.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.